Results 281 to 290 of about 171,342 (310)

Triple-negative breast tumors with a twist: a radiological and histological approach to salivary gland-type neoplasms

Learning objectives Background Findings and procedure details Conclusion Personal information and conflict of interest ...
openaire   +1 more source

Abstract PD1-01: Trilaciclib (T), a CDK4/6 inhibitor, dosed with gemcitabine (G), carboplatin (C) in metastatic triple negative breast cancer (mTNBC) patients: Preliminary phase 2 results

Poster Discussion Abstracts, 2019
Background: Cytotoxic chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPCs) results in acute toxicities consisting of multi-lineage myelosuppression, and late onset toxicities consisting of progressive bone marrow suppression ...
J. O’Shaughnessy, G. Wright, Anu R. Thummala, M. Danso, L. Popović, T. Pluard, E. Cheung, H. Han, B. Daniel, Ž. Vojnović, N. Vasev, M. Ling, D. Richards, S. Wilks, D. Milenković, J. Sorrentino, P. Roberts, M. Bomar, Z. Yang, J. Antal, R. Malik, S. Morris, A. Tan   +22 more
semanticscholar   +1 more source

Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches.

Journal of Controlled Release, 2021
Saikat Ghosh, Ankit Javia, Saritha Shetty, Denish Bardoliwala, K. Maiti, Shubhadeep Banerjee, Ajay Khopade, A. Misra, K. Sawant, S. Bhowmick   +9 more
semanticscholar   +1 more source

BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer

Cellular Oncology, 2022
F. De Santis, S. Romero-Cordoba, L. Castagnoli, Tatiana Volpari, S. Faraci, G. Fucà, E. Tagliabue, F. de Braud, S. Pupa, M. Di Nicola   +9 more
semanticscholar   +1 more source

Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.

International Immunopharmacology, 2021
Melina Farshbafnadi, Amin Pastaki Khoshbin, N. Rezaei   +2 more
semanticscholar   +1 more source

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Özge Gumusay, Damé Idossa   +2 more
exaly  

Triple-negative breast cancer: biology, pathology, and treatment

, 2021
A. Miri, E. Kiani, S. Habibi, M. Khafaei
semanticscholar   +1 more source

Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets

Cell Metabolism, 2021
Yue Gong, Yun-Song Yang, Tian-Jian Yu
exaly  

Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021

Cancers, 2022
Maroun Bou Zerdan, Tala Ghorayeb, Sabine Allam   +2 more
exaly  

Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy

Cell Metabolism, 2023
Yi Xiao
exaly